Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis

QR Code

Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis

Relevance. Pneumococci are among the most common causative agents of severe bacterial infections in humans. The prevalence of invasive pneumococcal infections among people with autoimmune inflammatory rheumatic diseases is 3–4 times higher than in the general population. Aim. To evaluate the effecti...

Full description

Saved in:

Bibliographic Details
Main Authors:	B. T. Batozhargalova, M. P. Kostinov, A. D. Shmitko, G. V. Lukina, D. A. Murtazalieva, E. N. Koltsova, E. V. Zhilyaev
Format:	Article
Language:	Russian
Published:	Numikom LLC 2024-03-01
Series:	Эпидемиология и вакцинопрофилактика
Subjects:	pcv13 vaccination rheumatoid arthritis immunogenicity safety
Online Access:	https://www.epidemvac.ru/jour/article/view/1942
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial
by: Courtney P. Olwagen, et al.
Published: (2024-12-01)

Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
by: B. Ts. Batozhargalova, et al.
Published: (2024-09-01)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024-12-01)

Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review
by: Aiko Shono, et al.
Published: (2025-12-01)

Epidemiology of S. Pneumoniae-associated Pneumonias and the Analysis of Effectiveness of Vaccination against Pneumococcal Infection in Children under the Age of Six
by: A. V. Somova, et al.
Published: (2018-02-01)

Analysis of Morbidity Dynamics and Factors Influencing the Development of Pneumococcal Infections among the Adult Population of the Sakha Republic (Yakutia)
by: A. N. Argunova, et al.
Published: (2018-09-01)

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
by: Masayoshi Shinjoh, et al.
Published: (2024-12-01)

ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES
by: M. S. Naumtseva, et al.
Published: (2016-02-01)

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy
by: Mark A. Fletcher, et al.
Published: (2024-12-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01)

IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A TWO-YEAR FOLLOW-UP STUDY
by: M. S. Naumtseva, et al.
Published: (2017-01-01)

The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis
by: M. S. Naumtseva, et al.
Published: (2015-08-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)

A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years
by: Jose Luis Huerta, et al.
Published: (2025-08-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024-12-01)

Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study
by: D. V. Bukhanova, et al.
Published: (2018-12-01)

Clinical and Economic Efficiency of Vaccination in a Pneumococcal 13-Valent Conjugate Vaccine in Patients with Chronic Bronchitis at a Young Age
by: G. L. Ignatova, et al.
Published: (2017-04-01)

Experience in Immunizing HIV-Infected Children against Pneumococcal Infection and Influenza
by: O. I. Nazarova, et al.
Published: (2020-09-01)

Immunogenicity, Safety, and Clinical Eﬀectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)
by: M. M. Baranova, et al.
Published: (2022-04-01)

The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy
by: Margarita A. Soloshenko, et al.
Published: (2017-10-01)

Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review
by: Marcellin Mengouo Nimpa, et al.
Published: (2025-05-01)

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
by: Ekaterina I. Alekseeva, et al.
Published: (2019-09-01)

Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China
by: Jing Qiu, et al.
Published: (2025-07-01)

Assessment of Safety, Immunogenicity and Preventive Efficacy of Prevenar-13 in Children with Bronchopulmonary Dysplasia
by: E. S. Zubova, et al.
Published: (2018-04-01)

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Wanqin Tang, et al.
Published: (2025-08-01)

Candidate antirheumatic genotherapeutic plasmid constructions have low immunogenicity
by: T. S. Nepomnyashchikh, et al.
Published: (2017-05-01)

PHARMACOECONOMIC EVALUATION OF ANTI-PNEUMOCOCCAL VACCINATION IN RISK GROUPS FOR THE PREVENTION OF COMMUNITY-ACQUIRED PNEUMONIA AMONG ADULTS IN THE ASTRAKHAN REGION
by: E. A. Orlova, et al.
Published: (2021-05-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Serotype diversity of <i>Streptococcus pneumoniae</i> in children with chronic bronchopulmonary pathology in the pre-vaccination and post-vaccination periods
by: T. M. Komyagina, et al.
Published: (2024-05-01)

Immunogenicity, efficacy and safety of the three-valent inactivated influenza split vaccine in patients with ankylosing spondylitis and psoriatic arthritis
by: M. M. Baranova, et al.
Published: (2024-06-01)

Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review
by: Raziyeh Niyati, et al.
Published: (2025-06-01)

A Decade of Experience in the use of 13-Valent Conjugated Polysaccharide Pneumococcal Vaccine in Russian Federation
by: N. I. Briko, et al.
Published: (2023-09-01)

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Pneumococcal Conjugate Vaccine in Healthy Toddlers in the Russian Federation: a Phase III Randomized Study
by: L. S. Namazova-Baranova, et al.
Published: (2023-01-01)

Analysis of the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar
by: S. A. Pyrkova, et al.
Published: (2019-10-01)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009-04-01)

Golimumab in the treatment of inflammatory diseases: A role of immunogenicity
by: D. E. Karateev
Published: (2016-01-01)

Estimation of 13-valent Pneumococcal Conjugate Vaccine Efficiency in Infants within National Immunization Schedule
by: Nikolay I. Briko, et al.
Published: (2019-09-01)

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018-10-01)